Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 16:10:36.
doi: 10.21037/tgh-25-7. eCollection 2025.

Dosing matters: DESTINY-CRC02 and the evolving treatment paradigm for HER2 positive colorectal cancer

Lindsay M Hannan  1 , Olatunji B Alese  1
Affiliations
Editorial

Dosing matters: DESTINY-CRC02 and the evolving treatment paradigm for HER2 positive colorectal cancer

Lindsay M Hannan et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: Colorectal cancer (CRC); human epidermal growth factor receptor 2 (HER2); trastuzumab deruxtecan.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-25-7/coif). O.B.A. reports research funding to institution: Taiho Oncology, Ipsen Pharmaceuticals, GSK, Bristol Myers Squibb, Boehringer Ingelheim, Xencor Inc., Cue Biopharma, Inc., Merck, Inhibitex Inc, and Arcus Biosciences Inc; consulting/advisory role: Ipsen Pharmaceuticals, GSK, Cue Biopharma, Inc., Abbvie, Taiho, Bristol Myers Squibb, AstraZeneca, Exelixis, Takeda, Boehringer Ingelheim, and Loxo Oncology; and involvement in Independent Data Monitoring Committee: Compass Therapeutics, Inc. The other author has no conflicts of interest to declare.

Comment on

References

    1. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738-46. 10.1016/S1470-2045(16)00150-9 - DOI - PubMed
    1. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015;28:1481-91. 10.1038/modpathol.2015.98 - DOI - PubMed
    1. Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 2016;238:562-70. 10.1002/path.4679 - DOI - PMC - PubMed
    1. Lee SM, Oh H. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification. Sci Rep 2024;14:11432. 10.1038/s41598-024-62096-x - DOI - PMC - PubMed
    1. Strach MC, Chakrabarty B, Nagaraju RT, et al. Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma. ESMO Open 2023;8:101619. 10.1016/j.esmoop.2023.101619 - DOI - PMC - PubMed